EANS-Adhoc: Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte™ Gel

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Contracts

28.01.2011

DURHAM, NC, January 28, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ &
SIX Swiss Exchange: OXBT) today announced it has signed a research
contract with Hackensack University Medical Center (HUMC) to research
wound healing properties of the Oxygen Biotherapeutics´ Wundecyte™
perfluorocarbon (PFC) and its novel oxygen-producing bandage for
treatment of full-thickness excisional wounds and partial thickness
burns. The preclinical study will also evaluate Wundecyte´s ability
to prevent scar formation and improve infection control. This project
will be funded by the U.S. Department of Defense.

Dr. Antoine Carlisle, a research scientist at HUMC, will be the
Principal Investigator. Oxygen Biotherapeutics researchers will work
closely with HUMC by participating in the study design and
investigator meetings.

According to Oxygen Biotherapeutics Chief Medical Officer Gerald L.
Klein, MD, "Wounds and burns are the most common injuries faced by
our soldiers daily. We believe that providing additional oxygen may
help heal wounds, fight infections and decrease scarring. Wundecyte,
our PFC gel used alone and in combination with a bandage that
releases oxygen to the damaged tissue site, may be particularly
useful in military applications. Naturally, if study results are
favorable, it may also have application for civilian injuries as
well. We look forward to working closely with HUMC on this important
study."

end of ad-hoc-announcement ==========================================
====================================== About Oxygen Biotherapeutics,
Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic
products that efficiently deliver oxygen to tissues in the body. The
company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier and liquid ventilation product called Oxycyte that is
being formulated for both intravenous and topical delivery. This
year, the company launched its DERMACYTE® line of oxygen-rich skin
care products. In addition, the company is focused on
perfluorocarbon-based oxygen carriers for use in traumatic brain
injury, decompression sickness, personal care, and topical wound
healing. More information is available at www.oxybiomed.com or
www.buydermacyte.com.

About Hackensack University Medical Center

Hackensack University Medical Center, a 775-bed teaching and research
hospital affiliated with the University of Medicine and Dentistry of
New Jersey – New Jersey Medical School, is the largest provider of
inpatient and outpatient services in the state of New Jersey. Founded
in 1888 with 12 beds and as Bergen County's first hospital,
Hackensack University Medical Center has demonstrated more than a
century of growth and progress. Today, this not-for-profit,
tertiary-care, teaching and research hospital serves as the hub of
healthcare for northern New Jersey and the New York metropolitan
area. Hackensack University Medical Center continues to grow in
response to the needs of its patient population.

Caution Regarding Forward-Looking Statements This news release
contains certain forward-looking statements by the company that
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include the expansion
of research and development of the Oxycyte product line, including
Wundecyte, and the timing of the introduction of those new products.
The forward-looking statements are subject to a number of risks and
uncertainties including matters beyond the company’s control that
could lead to delays in new product introductions and customer
acceptance of these new products, and other risks and uncertainties
as described in our filings with the Securities and Exchange
Commission, including in the current report on Form 10-Q filed on
September 9, 2010. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this
release. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard